27578983|t|EGFR protein expression using a specific intracellular domain antibody and PTEN and clinical outcomes in squamous cell lung cancer patients with EGFR-tyrosine kinase inhibitor therapy
27578983|a|The aim of this research was to examine the molecular and clinical features that are related with EGFR-tyrosine kinase inhibitor (EGFR-TKI) efficacy in previously treated patients with squamous cell carcinoma of the lung (SCCL). This retrospective study included 67 SCCL patients with obtainable lung cancer tissue and records on EGFR-TKI treatment response and survival. EGFR protein expression in lung cancer tissue was measured by immunohistochemistry with a specific antibody that recognizes the intracellular domain (ID) of EGFR. PTEN expression in lung cancer tissue was also evaluated with immunohistochemistry. PI3KCA gene amplification was detected by quantitative real-time polymerase chain reaction, and FGFR1 amplification was assessed by fluorescent in situ hybridization. EGFR ID expression (hazard ratio [HR] 0.53, P=0.022) and Eastern Cooperative Oncology Group (ECOG) performance status (PS) (HR 0.43, P=0.022) were significantly related with progression - free survival following EGFR-TKIs treatment. PTEN expression (HR 0.52, P=0.025) was significantly related to overall survival. The group of EGFR - positive or PTEN - positive patients with ECOG PS of 0 or 1 had better clinical outcomes than patients who were EGFR - negative and PTEN - negative or who had poor ECOG PS with longer median progression - free survival (2.1 vs 1.0 months, P=0.05) and overall survival (6.2 vs 2.1 months, P=0.05). EGFR expression using an ID -specific antibody and PTEN protein expression may be used to identify SCCL patients who might benefit from EGFR-TKI treatment.
27578983	0	12	EGFR protein	T116,T192	C1739039
27578983	13	23	expression	T045	C1171362
27578983	41	54	intracellular	T082	C0178719
27578983	55	61	domain	T087	C1514562
27578983	62	70	antibody	T116,T129	C0003241
27578983	75	79	PTEN	T116,T126	C1430988
27578983	84	101	clinical outcomes	T080	C0085415
27578983	105	130	squamous cell lung cancer	T191	C0149782
27578983	131	139	patients	T101	C0030705
27578983	145	183	EGFR-tyrosine kinase inhibitor therapy	T061	C3899317
27578983	188	191	aim	T078	C1947946
27578983	200	208	research	T062	C0035168
27578983	216	223	examine	T058	C0582103
27578983	228	237	molecular	T080	C1521991
27578983	242	250	clinical	T080	C0205210
27578983	251	259	features	T080	C2348519
27578983	282	312	EGFR-tyrosine kinase inhibitor	T061	C3899317
27578983	314	322	EGFR-TKI	T061	C3899317
27578983	324	332	efficacy	T080	C1280519
27578983	347	354	treated	T033	C0332154
27578983	355	363	patients	T101	C0030705
27578983	369	404	squamous cell carcinoma of the lung	T191	C0149782
27578983	406	410	SCCL	T191	C0149782
27578983	418	437	retrospective study	T062	C0035363
27578983	450	454	SCCL	T191	C0149782
27578983	455	463	patients	T101	C0030705
27578983	469	479	obtainable	T052	C1706701
27578983	480	491	lung cancer	T191	C0684249
27578983	492	498	tissue	T024	C0040300
27578983	503	510	records	T170	C0034869
27578983	514	532	EGFR-TKI treatment	T061	C3899317
27578983	533	541	response	T032	C0871261
27578983	546	554	survival	T052	C0038952
27578983	556	568	EGFR protein	T116,T192	C1739039
27578983	569	579	expression	T045	C1171362
27578983	583	594	lung cancer	T191	C0684249
27578983	595	601	tissue	T024	C0040300
27578983	606	614	measured	T080	C0444706
27578983	618	638	immunohistochemistry	T060	C0021044
27578983	655	663	antibody	T116,T129	C0003241
27578983	669	679	recognizes	T041	C0524637
27578983	684	697	intracellular	T082	C0178719
27578983	698	704	domain	T087	C1514562
27578983	706	708	ID	T087	C1514562
27578983	713	717	EGFR	T116,T192	C1739039
27578983	719	723	PTEN	T116,T126	C1430988
27578983	724	734	expression	T045	C1171362
27578983	738	749	lung cancer	T191	C0684249
27578983	750	756	tissue	T024	C0040300
27578983	766	775	evaluated	T058	C0220825
27578983	781	801	immunohistochemistry	T060	C0021044
27578983	803	828	PI3KCA gene amplification	T049	C3273085
27578983	833	841	detected	T033	C0442726
27578983	845	893	quantitative real-time polymerase chain reaction	T063	C3179034
27578983	899	918	FGFR1 amplification	T049	C1517090
27578983	923	931	assessed	T052	C1516048
27578983	935	968	fluorescent in situ hybridization	T063	C0162789
27578983	970	974	EGFR	T116,T192	C1739039
27578983	975	977	ID	T087	C1514562
27578983	978	988	expression	T045	C1171362
27578983	1027	1092	Eastern Cooperative Oncology Group (ECOG) performance status (PS)	T201	C1520224
27578983	1117	1130	significantly	T078	C0750502
27578983	1144	1155	progression	T191	C0178874
27578983	1158	1162	free	T169	C0332296
27578983	1163	1171	survival	T052	C0038952
27578983	1182	1201	EGFR-TKIs treatment	T061	C3899317
27578983	1203	1207	PTEN	T116,T126	C1430988
27578983	1208	1218	expression	T045	C1171362
27578983	1242	1255	significantly	T078	C0750502
27578983	1267	1274	overall	T080	C1561607
27578983	1275	1283	survival	T052	C0038952
27578983	1289	1294	group	T078	C0441833
27578983	1298	1302	EGFR	T116,T192	C1739039
27578983	1305	1313	positive	T033	C1446409
27578983	1317	1321	PTEN	T116,T126	C1430988
27578983	1324	1332	positive	T033	C1446409
27578983	1333	1341	patients	T101	C0030705
27578983	1347	1354	ECOG PS	T201	C1520224
27578983	1369	1393	better clinical outcomes	T033	C1333602
27578983	1399	1407	patients	T101	C0030705
27578983	1417	1421	EGFR	T116,T192	C1739039
27578983	1424	1432	negative	T033	C0205160
27578983	1437	1441	PTEN	T116,T126	C1430988
27578983	1444	1452	negative	T033	C0205160
27578983	1464	1468	poor	T080	C0542537
27578983	1469	1476	ECOG PS	T201	C1520224
27578983	1489	1495	median	T081	C0876920
27578983	1496	1507	progression	T191	C0178874
27578983	1510	1514	free	T169	C0332296
27578983	1515	1523	survival	T052	C0038952
27578983	1556	1563	overall	T080	C1561607
27578983	1564	1572	survival	T052	C0038952
27578983	1602	1606	EGFR	T116,T192	C1739039
27578983	1607	1617	expression	T045	C1171362
27578983	1627	1629	ID	T087	C1514562
27578983	1640	1648	antibody	T116,T129	C0003241
27578983	1653	1665	PTEN protein	T116,T126	C1430988
27578983	1666	1676	expression	T045	C1171362
27578983	1692	1700	identify	T080	C0205396
27578983	1701	1705	SCCL	T191	C0149782
27578983	1706	1714	patients	T101	C0030705
27578983	1725	1732	benefit	T081	C0086387
27578983	1738	1756	EGFR-TKI treatment	T061	C3899317